Paquinimod

SKU: orb1299932

Description

Paquinimod

Research Area

Infectious Disease & Virology

Key Properties

• CAS Number: 248282-01-1
• MW: 350.41
• Purity: 99.61%
• Formula: C₂₁H₂₂N₂O₃
• SMILES: CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1
• Target: SARS-CoV,Others
• Solubility: DMSO:123 mg/mL (351.02 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:12.5 mg/mL (35.67 mM)

Bioactivity

• In Vivo:
  Prophylactic treatment of paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and ameliorates pathological effects of S100A9 in OA synovium ex vivo.Treatment with paquinimod reduces skin fibrosis measured as reduction of skin thickness and decreased number of myofibroblasts and total hydroxyproline content. The effect on fibrosis was associated with a polarization of macrophages in the skin from a pro-fibrotic M2 to a M1 phenotype. Paquinimod treatment also resulted in a reduced TGFβ-response in the skin and an abrogation of the increased auto-antibody production in this SSc model.
• Animal Research:
  Two OA mouse models differing in level of synovial activation were treated prophylactic with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod.Seven weeks old female B6.Cg-Fbn1(Tsk)/J (Tsk-1) mice were treated with vehicle or paquinimod at the dose of 5 or 25mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level of skin fibrosis and on different subpopulations within the myeloid cell compartment in skin biopsies were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR. Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses were performed using Mann-Whitney nonparametric two tailed rank test.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Paquinimod, inhibit, Inhibitor, ABR 25757, ABR25757, ABR-25757, S100A9

Compound Identifiers

PubChem CID

54684617